The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency

NCT03039335 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2018-07-16

No results posted yet for this study

Summary

The objective of this study is to prospectively assess whether there is any interval between first symptom and initial diagnosis that is experienced by patients with newly diagnosed alpha-1 antitrypsin deficiency (AATD) and then to assess whether this diagnostic interval is associated with worsened clinical status at the time of initial diagnosis.

Conditions

Sponsors & Collaborators

  • Biocerna LLC

    lead INDUSTRY

Principal Investigators

  • Christopher Sanders · CEO of Biocerna LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-15
Primary Completion
2018-04-15
Completion
2018-04-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03039335 on ClinicalTrials.gov